PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 23, 2021Annals of Oncology214 citationsOpen Access

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

GCGiuseppe CuriglianoVMVolkmar MuellerVBVirginia F. Borges

Key Points

Key points are not available for this paper at this time.

Abstract

With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Curigliano et al. (2021) studied this question.

synapsesocial.com/papers/69d8d88a13e0539d74bedc6dhttps://doi.org/10.1016/j.annonc.2021.12.005
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial2020 · 558 citations
  2. 2Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)2021 · 14 citations
  3. 3Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.1998 · 1,926 citations
  4. 4Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987 · 11,808 citations
  5. 5Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer2013 · 130 citations